CathRx opens IPO for listing next month
23 September, 2005 by Helen SchullerSydney medical device company CathRx has opened its initial public offering and aims to raise AUD$14 million before listing on the ASX in late October.
New drug discovery facility for Melbourne
22 September, 2005 by Ruth BeranThe privately funded Australian Cancer Research Foundation (ACRF) has awarded a grant of AUD$900,000 to Melbourne's St Vincent's Institute (SVI) to establish a rational drug discovery facility for cancer research.
Vaxine awarded $2.5m bioterrorism grant
21 September, 2005 by Ruth BeranPrivately-held vaccine developer Vaxine and Flinders University have been awarded a grant of US$2.5 million over three years by the US National Institutes of Health (NIH) to develop vaccines that protect against bioterrorist attacks.
Biota aims to raise $10m
21 September, 2005 by Ruth BeranMelbourne-based Biota Holdings (ASX:BTA) is aiming to raise more than AUD$10 million in a non-renounceable share offer to existing shareholders.
Mesoblast to start commercial stem cell production
21 September, 2005 by Ruth BeranMelbourne-based Mesoblast (ASX:MSB) has signed a process development and manufacturing agreement with US life sciences company Cambrex Corporation (NYSE:CMB) for the large scale production of Mesoblast's adult stem cells.
Local pharma firms to distribute Funhaler
21 September, 2005 by Helen SchullerPerth-based biomedical devices developer Visiomed Group (ASX:VSG) has successfully competed negotiations with three pharmaceutical wholesale distributors in Australia for the distribution of its Funhaler incentive asthma spacer into Australian pharmacies.
Ventracor chalks up first revenues
20 September, 2005 by Ruth BeranVentracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.
Premier subsidiary to go ahead with lung device
20 September, 2005 by Helen SchullerPremier Bionics (ASX:PBI) subsidiary Pulmosonix will continue with the development of its PulmoScreen device which measures lung damage following the successful completion of a proof-of-concept trial.
Medical Therapies narrows focus, issues new prospectus
20 September, 2005 by Helen SchullerUnable to secure sufficient funds with its first attempt at an IPO, Sydney-based Medical Therapies has issued a replacement prospectus which CEO Llewellyn Casbolt believes has "uncluttered and demystified the company and its technologies".
Eqitx, Mimotopes sign partnering deal
19 September, 2005 by Ruth BeranEqitx (ASX:EQX) and PharmAust (ASX:PAA) subsidiary Mimotopes have signed a partnership deal to jointly develop new targets for therapeutic or diagnostic approaches.
Cryptome to chase opps in vascular field
19 September, 2005 by Helen SchullerMelbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has signed a collaboration agreement with the University of Virginia for the further discovery of compounds to treat 'vascular leak' -- a major component of inflammatory disorders and tissue damage associated with stroke, heart attacks and MS.
EvoGenix licenses leukaemia antibody
19 September, 2005 by Ruth BeranAntibody developer EvoGenix (ASX:EGX) has signed a licensing deal with Dinona for one of the South Korean biotech's anti-leukaemia antibodies.
CogState turns focus from biotech
19 September, 2005 by Helen SchullerMelbourne-based CogState (ASX:CGS) has distanced itself from the biotech sector, in a move that CEO Peter Bick described as "bowing to popular pressure that biotechs are highly risky and expensive businesses".
Avastra files for new BioWeld patent
16 September, 2005 by Ruth BeranSydney-based Avastra (ASX:AVS) has filed a provisional patent on the use of its BioWeld technology in conjunction with surgical glues and adhesives.
Starpharma investee Dimerix raises $1m
16 September, 2005 by Helen SchullerDimerix Bioscience has closed a series A capital raising worth almost AUD$1 million, and has revealed plans to accelerate the development of its new compounds created by applying its technologies to novel G-protein coupled receptor (GPCR) cluster targets.
